John A Orwin is of Travere Therapeutics, Inc.. Currently has a direct ownership of 28,875 shares of TVTX, which is worth approximately $527,257. The most recent transaction as insider was on May 08, 2024, when has been sold 6,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28.9K
0% 3M change
29.05% 12M change
Total Value Held $527,257

John A Orwin Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 08 2024
BUY
Grant, award, or other acquisition
-
6,500 Added 18.37%
28,875 Common Stock
May 17 2023
BUY
Grant, award, or other acquisition
-
4,500 Added 16.74%
22,375 Common Stock
May 11 2022
BUY
Grant, award, or other acquisition
-
3,000 Added 14.37%
17,875 Common Stock
May 14 2021
BUY
Grant, award, or other acquisition
-
3,000 Added 16.78%
14,875 Common Stock

Also insider at

BCEL
Atreca, Inc. Healthcare
SGEN
Seagen Inc. Healthcare
ANAB
ANAPTYSBIO, INC Healthcare
CRGX
CARGO Therapeutics, Inc.
JAO

John A Orwin

San Carlos, CA

Track Institutional and Insider Activities on TVTX

Follow Travere Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

News

Receive news related to Travere Therapeutics, Inc.

Track Activities on TVTX